Special Issue "Herbal Medicine for the Treatment of Fatty Liver Disease"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 250

Special Issue Editors

Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Interests: epidemiology; network pharmacology; obesity; cancer; kidney disease
Division of General Surgery, Département of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan
Interests: hepatocellular carcinoma; surgical oncology; minimal invasive surgery

Special Issue Information

Dear Colleagues,

Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder that has gradually become one of the most common non-communicable diseases in recent decades. On the other hand, as a chronic disease with heterogenous etiologies, complicated pathogenesis, and multiple co-morbidities, NAFLD may progress to non-alcoholic steatohepatitis (NASH) and even cirrhosis if it cannot be managed appropriately. However, despite the impact on the healthcare system, the medical therapies for NAFLD are still limited, for example, GLP-1 and PPARγ mimetics. Therefore, new agents with or without non-pharmacological treatments (exercise, lifestyle or diet modification, etc.) are still needed. 
Herbal medicine (HM) has been used in many countries for thousands of years. It is reported that several HMs have anti-NAFLD effects through modulating lipid metabolisms, oxidative stress, autophagy, and other mechanisms. For instance, Torenia concolor Lindley var. formosana Yamazaki has been found to be beneficial to alleviate inflammation effects from lipid accumulation in fat-cell models. Resveratrol has been reported to have the ability to enhance autophagy and reduce oxidative stress and fibrosis. On the other hand, management of the NAFLD-related co-morbidities, such as obesity, metabolic syndrome, hyperlipidemia, and polycystic ovarian syndrome, is also essential to deal with NAFLD since there are complex interactions between NAFLD and its co-morbidities. 
The purpose of this Special Issue is to investigate the feasibility of HM in managing NAFLD. Clinical, in vitro, or in vivo studies are all welcome for submission to this Special Issue.

Dr. Hsing-Yu Chen
Dr. Chao-Wei Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • non-alcoholic fatty liver disease
  • herbal medicine
  • clinical trial
  • cohort
  • case–control
  • in vivo
  • in vitro

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop